Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from BioHarvest Sciences ( (BHST) ).
BioHarvest Sciences Inc. announced on March 17, 2026, that it will report its fourth quarter and full year 2025 financial results after the market close on Tuesday, March 31, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to review the results and provide an update on its business operations.
The earnings webcast will be streamed live, with investors encouraged to register in advance, and a replay will later be posted in the Investor Relations section of BioHarvest’s website. The timing underscores BioHarvest’s ongoing effort to maintain active engagement with shareholders and analysts as it advances its Botanical Synthesis platform across CDMO and nutraceutical markets.
The most recent analyst rating on (BHST) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by weak financial performance (ongoing net losses, negative operating/free cash flow, and elevated leverage) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improving gross margins, and guidance pointing toward adjusted EBITDA breakeven, but valuation remains constrained by unprofitability and no dividend.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company listed on Nasdaq and Frankfurt that specializes in its proprietary Botanical Synthesis platform, which produces plant-based compounds without growing the whole plant. The company operates as both a contract development and manufacturing organization for customers seeking novel plant-derived ingredients and as a developer of proprietary nutraceutical health and wellness products, including dietary supplements.
Average Trading Volume: 31,335
Technical Sentiment Signal: Buy
Current Market Cap: $103.5M
Learn more about BHST stock on TipRanks’ Stock Analysis page.